Photodynamic Therapy in Treating Patients With Lymphoma or Chronic Lymphocytic Leukemia
Phase 2
Completed
- Conditions
- LeukemiaLymphoma
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 1
- Registration Number
- NCT00054171
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer Who Have Undergone Surgery or Radiation Therapy
Phase 2
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2011-03-08
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 15
- Registration Number
- NCT00054522
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
πΊπΈHillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma
Phase 2
Completed
- Conditions
- Malignant Mesothelioma
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2011-03-01
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT00054002
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Lung Cancer
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00054314
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
Phase 2
Completed
- Conditions
- Multiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative DiseasesChronic Myeloproliferative DisordersFanconi AnemiaAplastic AnemiaLeukemiaLymphoma
- Interventions
- Biological: anti-thymocyte globulinBiological: graft-versus-tumor induction therapyBiological: sargramostimBiological: therapeutic allogeneic lymphocytesProcedure: allogeneic bone marrow transplantationProcedure: peripheral blood stem cell transplantationProcedure: umbilical cord blood transplantation
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 41
- Registration Number
- NCT00053989
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
Phase 1
Completed
- Conditions
- Leukemia
- First Posted Date
- 2003-01-28
- Last Posted Date
- 2011-03-08
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00053144
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Phase 2
Completed
- Conditions
- Leukemia
- First Posted Date
- 2003-01-28
- Last Posted Date
- 2011-03-08
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00053131
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer
Phase 1
Completed
- Conditions
- Brain and Central Nervous System TumorsLymphomaNeuroblastomaRetinoblastoma
- First Posted Date
- 2003-01-28
- Last Posted Date
- 2011-03-01
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 1
- Registration Number
- NCT00053118
- Locations
- πΊπΈ
St. Louis Children's Hospital, Saint Louis, Missouri, United States
πΊπΈRoswell Park Cancer Institute, Buffalo, New York, United States
πΊπΈUniversity of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia
Not Applicable
Completed
- Conditions
- LymphomaChronic Myeloproliferative DisordersLeukemiaMyelodysplastic/Myeloproliferative NeoplasmsGraft Versus Host DiseaseMyelodysplastic Syndromes
- First Posted Date
- 2003-01-28
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT00053157
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States
Photodynamic Therapy in Treating Patients With Skin Cancer
Phase 2
Completed
- Conditions
- Precancerous ConditionNon-melanomatous Skin Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-10-10
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 180
- Registration Number
- NCT00002975
- Locations
- πΊπΈ
Roswell Park Cancer Institute, Buffalo, New York, United States